Karyopharm Therapeutics Inc. (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $9.16, for a total value of $91,600.00. Following the sale, the chief executive officer now owns 522,143 shares in the company, valued at $4,782,829.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Karyopharm Therapeutics Inc. (KPTI) remained flat at $$9.15 on Wednesday. 173,400 shares of the company were exchanged, compared to its average volume of 234,014. Karyopharm Therapeutics Inc. has a 1-year low of $7.48 and a 1-year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. research analysts forecast that Karyopharm Therapeutics Inc. will post -2.58 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC increased its position in Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after acquiring an additional 4,444 shares during the period. Tudor Investment Corp ET AL acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at approximately $136,000. Trexquant Investment LP acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at approximately $202,000. State of Wisconsin Investment Board acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at approximately $235,000. Finally, The Manufacturers Life Insurance Company increased its position in Karyopharm Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after acquiring an additional 5,586 shares during the period. Hedge funds and other institutional investors own 60.92% of the company’s stock.

A number of brokerages have recently weighed in on KPTI. Royal Bank of Canada reiterated a “buy” rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, October 18th. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 12th. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Finally, Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $17.33.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/20/karyopharm-therapeutics-inc-kpti-ceo-sells-91600-00-in-stock.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.